Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy-Reference-Cited by-同舟云学术

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

Published:2019-01-16 Issue:2 Volume:3 Page:132-135
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Landsburg Daniel J.¹,Hughes Mitchell E.²^ORCID,Koike Alexa³,Bond David⁴,Maddocks Kami J.⁴,Guo Ling⁵,Winter Allison M.⁶,Hill Brian T.⁶,Ondrejka Sarah L.⁷,Hsi Eric D.⁷,Nasta Sunita D.¹,Svoboda Jakub¹,Schuster Stephen J.¹,Bogusz Agata M.³

Affiliation:

1. Department of Medicine,

2. Department of Pharmacy, and

3. Department of Pathology, University of Pennsylvania, Philadelphia, PA;

4. Department of Internal Medicine and

5. Department of Pathology, The Ohio State University, Columbus, OH; and

6. Department of Hematology/Oncology and

7. Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH

Abstract

Key Points The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/2/132/1630728/advances026401.pdf

Reference15 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016

2. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program;Hu;Blood,2013

3. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone;Green;J Clin Oncol,2012

4. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone;Johnson;J Clin Oncol,2012

5. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation;Herrera;J Clin Oncol,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B , high TCL1A expression, or over- expressed MYC/BCL-2;Leukemia & Lymphoma;2024-05-22

2. A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia;Leukemia Research Reports;2024

3. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach;The Lancet Haematology;2023-12

4. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies;Experimental Hematology & Oncology;2023-10-16

5. Clinicopathologic and genetic features of the starry-sky pattern in double-expressor diffuse large B-cell lymphoma;Human Pathology;2023-09